{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00669",
      "entity_text" : "AVB.1",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:O75390",
      "entity_text" : "CS",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Currently, all CS guidelines recommend both CIED and immune-suppression therapy for management of CS induced AVB.1, 2, 3 Despite the potential reversibility of AVB, all CS guidelines strongly recommend permanent CIED implantation due to the unpredictable disease course.1, 2, 3 Therefore, the primary role of immune-suppression is secondary prevention of cardiac dysfunction and ventricular arrhythmias.",
  "reading_complete" : "2020-08-02T08:35:19Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T08:34:36Z",
  "trigger" : "induced",
  "evidence" : [ "CS-induced AVB.1" ],
  "pmc_id" : "6509926",
  "score" : 0
}